Detalles de la búsqueda
1.
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
Cancer
; 123(2): 253-262, 2017 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27648814
2.
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Cancer
; 123(12): 2303-2311, 2017 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28171710
3.
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research.
Future Oncol
; 12(23): 2689-2699, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27528114
4.
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
Lancet Oncol
; 15(10): 1147-56, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25104109
5.
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Clin Genitourin Cancer
; 15(5): 610-617.e3, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28344102
6.
Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
Circulation
; 108(11): 1310-5, 2003 Sep 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-12939212
7.
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Eur Urol
; 68(5): 795-801, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25698064
Resultados
1 -
7
de 7
1
Próxima >
>>